CMS and FDA launch RAPID pathway to speed Medicare coverage for breakthrough devices
CMS and the FDA have unveiled a new coverage pathway designed to shorten the lag between a breakthrough device’s regulatory approval and Medicare reimbursement. The move could materially improve early patient access, especially for devices aimed at urgent or life-altering conditions. But the policy also raises questions about how much evidence will be enough when coverage decisions are being made faster than ever.
The Centers for Medicare & Medicaid Services and the FDA are taking a notable step toward closing one of medtech’s longest-running bottlenecks: the gap between approval and payment. Their new RAPID pathway is meant to streamline Medicare coverage for breakthrough medical devices, a process that has historically been slow, uncertain, and expensive for manufacturers.
That matters because reimbursement, not clearance, often determines whether a device actually reaches patients. A company can win FDA authorization and still struggle to launch if hospitals and physicians cannot count on Medicare coverage. By aligning the two agencies more closely, Washington is signaling that it wants breakthrough technology to move from regulatory success to clinical adoption more quickly.
The policy could be especially consequential for smaller device developers, which often lack the capital to survive a long coverage delay. Faster coverage decisions may reduce financing risk, improve investor confidence, and make it easier for innovators to plan commercial launches. In practical terms, this could accelerate adoption in areas such as imaging, cardiac care, and remote monitoring, where evidence may be promising but market access has been inconsistent.
Still, the speedup creates a familiar tradeoff. Faster reimbursement can help patients, but it also puts pressure on CMS to make coverage calls with less mature evidence. The real test of RAPID will be whether it can preserve post-market scrutiny while avoiding the years-long limbo that has frustrated device makers and clinicians alike.